Having trouble accessing articles? Reset your cache.

Enanta dips on concerns about pruritus, differentiation of NASH compound

Dose selection for an upcoming trial could prove crucial among Enanta’s next steps for its FXR agonist following a Phase II readout in NASH that raised questions about the compound’s tolerability and differentiation from others in its class.

Enanta shed more than $200 million in market cap Thursday

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers